CCL

Összesen 4 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM069431
Első szerző:Farmakis, Dimitrios
Cím:Levosimendan beyond inotropy and acute heart failure : evidence of pleiotropic effects on the heart and other organs : an expert panel position paper / Farmakis Dimitrios, Alvarez Julian, Gal Tuvia Ben, Brito Dulce, Fedele Francesco, Fonseca Candida, Gordon Anthony C., Gotsman Israel, Grossini Elena, Guarracino Fabio, Harjola Veli-Pekka, Hellman Yaron, Heunks Leo, Ivancan Visnja, Karavidas Apostolos, Kivikko Matti, Lomivorotov Vladimir, Longrois Dan, Masip Josep, Metra Marco, Morelli Andrea, Nikolaou Maria, Papp Zoltán, Parkhomenko Alexander, Poelzl Gerhard, Pollesello Piero, Ravn Hanne Berg, Rex Steffen, Riha Hynek, Ricksten Sven-Erik, Schwinger Robert H. G., Vrtovec Bojan, Yilmaz M. Birhan, Zielinska Marzenna, Parissis John
Dátum:2016
ISSN:0167-5273
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:International Journal Of Cardiology 222 (2016), p. 303-312. -
További szerzők:Alvarez, Julian Gal, Tuvia Ben Brito, Dulce Fedele, Francesco Fonseca, Candida Gordon, Anthony C. Gotsman, Israel Grossini, Elena Guarracino, Fabio Harjola, Veli-Pekka Hellman, Yaron Heunks, Leo Ivancan, Visnja Karavidas, Apostolos Kivikko, Matti Lomivorotov, Vladimir Longrois, Dan Masip, Josep Metra, Marco Morelli, Andrea Nikolaou, Maria Papp Zoltán (1965-) (kardiológus, élettanász) Parkhomenko, Alexander Poelzl, Gerhard Pollesello, Piero Ravn, Hanne Berg Rex, Steffen Riha, Hynek Ricksten, Sven-Erik Schwinger, Robert H. G. Vrtovec, Bojan Yilmaz, Mehmet Birhan Zielinska, Marzenna Parissis, John
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM090883
Első szerző:Papp Zoltán (kardiológus, élettanász)
Cím:Levosimendan Efficacy and Safety : 20 Years of SIMDAX in Clinical Use / Papp Zoltán, Agostoni Piergiuseppe, Alvarez Julian, Bettex Dominique, Bouchez Stefan, Brito Dulce, Černý Vladimir, Comin-Colet Josep, Crespo-Leiro Marisa G., Delgado Juan F., Édes Istvan, Eremenko Alexander A., Farmakis Dimitrios, Fedele Francesco, Fonseca Cândida, Fruhwald Sonja, Girardis Massimo, Guarracino Fabio, Harjola Veli-Pekka, Heringlake Matthias, Herpain Antoine, Heunks Leo M. A., Husebye Trygve, Ivancan Višnja, Karason Kristjan, Kaul Sundeep, Kivikko Matti, Kubica Janek, Masip Josep, Matskeplishvili Simon, Mebazaa Alexandre, Nieminen Markku S., Oliva Fabrizio, Papp Julius-Gyula, Parissis John, Parkhomenko Alexander, Põder Pentti, Pölzl Gerhard, Reinecke Alexander, Ricksten Sven-Erik, Riha Hynek, Rudiger Alain, Sarapohja Toni, Schwinger Robert H. G., Toller Wolfgang, Tritapepe Luigi, Tschöpe Carsten, Wikström Gerhard, von Lewinski Dirk, Vrtovec Bojan, Pollesello Piero
Dátum:2020
ISSN:0160-2446
Megjegyzések:Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute HF arena in recent times and charts a possible development trajectory for the next 20 years.
Papp Zoltán (1965-) (kardiológus, élettanász): Levosimendan Efficacy and Safety : 20 years of SIMDAX in Clinical Use
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Journal Of Cardiovascular Pharmacology. - 76 : 1 (2020), p. 4-22. -
További szerzők:Agostoni, Piergiuseppe Alvarez, Julian Bettex, Dominique Bouchez, Stefan Brito, Dulce Cerny, Vladimir Comin-Colet, Josep Crespo-Leiro, Maria G. Delgado, Juan F. Édes István (1952-) (kardiológus) Eremenko, Alexandr A. Farmakis, Dimitrios Fedele, Francesco Fonseca, Candida Fruhwald, Sonja Girardis, Massimo Guarracino, Fabio Harjola, Veli-Pekka Heringlake, Matthias Herpain, Antoine Heunks, Leo M. A. Husebye, Trygve Ivancan, Visnja Karason, Kristian Kaul, Sundeep Kivikko, Matti Kubica, Janek Masip, Josep Matskeplishvili, Simon Mebazaa, Alexandre Nieminen, Markku S. Oliva, Fabrizio Papp Gy. Julius (Szeged) Parissis, John Parkhomenko, Alexander Põder, Pentti Pölzl, Gerhard Reinecke, Alexander Ricksten, Sven-Erik Riha, Hynek Rudiger, Alain Sarapohja, Toni Schwinger, Robert H. G. Toller, Wolfgang Tritapepe, Luigi Tschöpe, Carsten Wikström, Gerhard von Lewinski, Dirk Vrtovec, Bojan Pollesello, Piero
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
   Lásd még:
Egyéb kapcsolat (1)
Borító:

3.

001-es BibID:BIBFORM090869
035-os BibID:(cikkazonosító)e19
Első szerző:Papp Zoltán (kardiológus, élettanász)
Cím:Levosimendan Efficacy and Safety : 20 years of SIMDAX in Clinical Use / Papp Zoltán, Agostoni Piergiuseppe, Alvarez Julian, Bettex Dominique, Bouchez Stefan, Brito Dulce, Černý Vladimir, Comin-Colet Josep, Crespo-Leiro Marisa G., Delgado Juan F., Édes Istvan, Eremenko Alexander A., Farmakis Dimitrios, Fedele Francesco, Fonseca Cândida, Fruhwald Sonja, Girardis Massimo, Guarracino Fabio, Harjola Veli-Pekka, Heringlake Matthias, Herpain Antoine, Heunks Leo M. A., Husebye Trygve, Ivancan Višnja, Karason Kristjan, Kaul Sundeep, Kivikko Matti, Kubica Janek, Masip Josep, Matskeplishvili Simon, Mebazaa Alexandre, Nieminen Markku S., Oliva Fabrizio, Papp Julius-Gyula, Parissis John, Parkhomenko Alexander, Põder Pentti, Pölzl Gerhard, Reinecke Alexander, Ricksten Sven-Erik, Riha Hynek, Rudiger Alain, Sarapohja Toni, Schwinger Robert H. G., Toller Wolfgang, Tritapepe Luigi, Tschöpe Carsten, Wikström Gerhard, von Lewinski Dirk, Vrtovec Bojan, Pollesello Piero
Dátum:2020
Megjelenés:Utánközlés / Másodközlés
ISSN:2057-7540 2057-7559
Megjegyzések:Levosimendan was first approved for clinic use in 2000, when authorisation was granted by Swedish regulatory authorities for the haemodynamic stabilisation of patients with acutely decompensated chronic heart failure. In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitisation and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced heart failure, right ventricular failure and pulmonary hypertension, cardiac surgery, critical care and emergency medicine. Levosimendan is currently in active clinical evaluation in the US. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and non-cardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, UK and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute heart failure arena in recent times and charts a possible development trajectory for the next 20 years.
Papp Zoltán (1965-) (kardiológus, élettanász): Levosimendan Efficacy and Safety : 20 Years of SIMDAX in Clinical Use
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Cardiac Failure Review. - 6 (2020), p. 1-16. -
További szerzők:Agostoni, Piergiuseppe Alvarez, Julian Bettex, Dominique Bouchez, Stefan Brito, Dulce Cerny, Vladimir Comin-Colet, Josep Crespo-Leiro, Maria G. Delgado, Juan F. Édes István (1952-) (kardiológus) Eremenko, Alexandr A. Farmakis, Dimitrios Fedele, Francesco Fonseca, Candida Fruhwald, Sonja Girardis, Massimo Guarracino, Fabio Harjola, Veli-Pekka Heringlake, Matthias Herpain, Antoine Heunks, Leo M. A. Husebye, Trygve Ivancan, Visnja Karason, Kristian Kaul, Sundeep Kivikko, Matti Kubica, Janek Masip, Josep Matskeplishvili, Simon Mebazaa, Alexandre Nieminen, Markku S. Oliva, Fabrizio Papp Gy. Julius (Szeged) Parissis, John Parkhomenko, Alexander Põder, Pentti Pölzl, Gerhard Reinecke, Alexander Ricksten, Sven-Erik Riha, Hynek Rudiger, Alain Sarapohja, Toni Schwinger, Robert H. G. Toller, Wolfgang Tritapepe, Luigi Tschöpe, Carsten Wikström, Gerhard von Lewinski, Dirk Vrtovec, Bojan Pollesello, Piero
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
   Lásd még:
Utánközlés (1)
Borító:

4.

001-es BibID:BIBFORM070112
Első szerző:Seferović, Petar M.
Cím:Organization of heart failure management in European Society of Cardiology member countries : survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups / Seferović Petar M., Stoerk Stefan, Filippatos Gerasimos, Mareev Viacheslav, Kavoliuniene Ausra, Ristić Arsen D., Ponikowski Piotr, McMurray John, Maggioni Aldol, Ruschitzka Frankl, van Veldhuisen Dirk J., Coats Andrew, Piepoli Massimo, McDonagh Theresa, Riley Jillian, Hoes Arno, Pieske Burkert, Dobrić Milan, Papp Zoltan, Mebazaa Alexandre, Parissis John, Ben Gal Tuvia, Vinereanu Dragos, Brito Dulce, Altenberger Johann, Gatzov Plamen, Milinković Ivan, Hradec Jaromír, Trochu Jean-Noel, Amir Offer, Moura Brenda, Lainscak Mitja, Comin Josep, Wikström Gerhard, Anker Stefan, Committee of National Heart Failure Societies or Working Groups of the Heart Failure Association of the European Society of Cardiology
Dátum:2013
ISSN:1388-9842
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:European Journal Of Heart Failure. - 15 : 9 (2013), p. 947-959. -
További szerzők:Stoerk, Stefan Filippatos, Gerasimos S. Mareev, Vyacheslev Kavoliuniene, Ausra Ristić, Arsen D. Ponikowski, Piotr McMurray, John J. Maggioni, Aldo Ruschitzka, Frank van Veldhuisen, Dirk J. Coats, Andrew Piepoli, Massimo McDonagh, Theresa Riley, Jillian Hoes, Arno Pieske, Burkert Dobrić, Milan Papp Zoltán (1965-) (kardiológus, élettanász) Mebazaa, Alexandre Parissis, John Ben Gal, Tuvia Vinereanu, Dragos Brito, Dulce Altenberger, Johann Gatzov, Plamen Milinković, Ivan Hradec, Jaromír Trochu, Jean-Noel Amir, Offer Moura, Brenda Lainscak, Mitja Comin-Colet, Josep Wikström, Gerhard Anker, Stefan D. Committee of NHFS or WGHFA of the ESC
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1